"Urologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the URINARY TRACT in either the male or the female.
| Descriptor ID |
D014571
|
| MeSH Number(s) |
C04.588.945.947 C12.758.820 C13.351.937.820
|
| Concept/Terms |
Urologic Neoplasms- Urologic Neoplasms
- Urological Neoplasms
- Neoplasm, Urological
- Neoplasms, Urological
- Urological Neoplasm
- Urinary Tract Neoplasms
- Neoplasm, Urinary Tract
- Neoplasms, Urinary Tract
- Tract Neoplasm, Urinary
- Tract Neoplasms, Urinary
- Urinary Tract Neoplasm
- Neoplasms, Urologic
- Neoplasm, Urologic
- Urologic Neoplasm
Cancer of Urinary Tract- Cancer of Urinary Tract
- Urinary Tract Cancers
- Urological Cancer
- Cancer, Urological
- Cancers, Urological
- Urological Cancers
- Cancer of the Urinary Tract
- Urinary Tract Cancer
- Cancer, Urinary Tract
- Cancers, Urinary Tract
- Urologic Cancer
- Cancer, Urologic
- Cancers, Urologic
- Urologic Cancers
|
Below are MeSH descriptors whose meaning is more general than "Urologic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Urologic Neoplasms".
This graph shows the total number of publications written about "Urologic Neoplasms" by people in this website by year, and whether "Urologic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 3 |
| 2014 | 3 | 0 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Urologic Neoplasms" by people in Profiles.
-
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211. Urol Oncol. 2025 Mar; 43(3):188.e9-188.e17.
-
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol. 2025 Apr; 8(2):258-262.
-
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2025 Feb; 23(1):102284.
-
Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience. Am J Clin Pathol. 2024 Nov 04; 162(5):492-499.
-
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10). Urol Oncol. 2025 May; 43(5):330.e1-330.e9.
-
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011. Cancer. 2025 Jan 01; 131(1):e35601.
-
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer. 2024 Dec; 22(6):102198.
-
Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis. Urol Oncol. 2024 Nov; 42(11):361-369.
-
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-?-induced Apoptosis in Urothelial Cancer. Anticancer Res. 2024 May; 44(5):1925-1930.
-
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectr. 2024 Apr 30; 8(3).